-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In October 2021, in Advanced Materials (Impact Factor 30.
849, in JCR "Materials Science, Multidisciplinary"), Professor Li Qian's team from the Anesthesiology and Surgery Center of West China Hospital, Sichuan University cooperated with Assistant Researcher Huo Minfeng, a member of the research team of Shi Jianlin, Shanghai Institute of Ceramics, Chinese Academy of Sciences.
"Ischemic Microenvironment-Responsive Therapeutics for Cardiovascular Diseases", published a review article "Ischemic Microenvironment-Responsive Therapeutics for Cardiovascular Diseases", which systematically summarizes the research progress of targeted smart biomaterials for the treatment of ischemic myocardial injury in recent years.
And provide new insights for the design and development of new treatment strategies in the future
.
The first authors of the article are research assistant Li Xi and postdoctoral fellow Zhang Yabing from the Center for Anesthesia and Surgery, West China Hospital, Sichuan University, and the corresponding authors are Professor Li Qian from the Center for Anesthesia and Surgery, West China Hospital, Sichuan University and Assistant Researcher Huo Minfeng, Shanghai Institute of Silicate, Chinese Academy of Sciences, West China, Sichuan University The hospital is the first author unit
.
Myocardial ischemic injury has a high mortality rate and poor prognosis.
Although the currently used drugs have a certain myocardial protection effect, due to the distribution of intravenous or oral drugs in the body, the bioavailability is reduced, and the therapeutic effect may be greatly reduced
.
Responsive biomaterials designed based on the characteristic ischemic microenvironment (IME) of the heart can target the delivery of therapeutic drugs to damaged cardiomyocytes, and have great therapeutic potential and application prospects in the field of ischemic cardiomyopathy
Schematic diagram of IME response treatment strategy for ischemic heart disease
This article systematically introduces the pathophysiological characteristics and microenvironmental changes of ischemic cardiomyopathy, and sorts out reactive oxygen species targeting, mitochondrial targeting, pH response, hypoxia response, matrix metalloproteinase response, and platelet and neutrophil membrane coating.
Design principles, synthesis methods, and mechanisms of action of intelligent targeted drug delivery systems; focusing on the therapeutic effects of a variety of representative nano-drugs or intelligent delivery systems in animal models of ischemic cardiomyopathy, and analyzing possible clinical outcomes The application prospect provides new ideas for the design and development of safe and effective treatment strategies for ischemic cardiomyopathy
.
For example, reactive oxygen species are significantly increased in ischemic cardiomyopathy.
Enrichment of reactive oxygen species-responsive nanocarriers in myocardial ischemia
In addition, ferroptosis is closely related to myocardial ischemic injury.
In response to this feature, the research group used polydopamine nanoparticles (PDA NPs) with good biocompatibility to target ferroptosis for the treatment of myocardial ischemia-reperfusion injury.
2]
.
In a mouse model of myocardial ischemia-reperfusion injury, pretreatment with PDA NPs effectively reduced myocardial infarct size in the ischemic region, improved cardiac function and reduced ischemia-induced myocardial fibrosis by inhibiting ferroptosis
Targeted ferroptosis in the treatment of myocardial ischemia-reperfusion injury
This paper also discusses and prospects the design and application of biomaterials in the treatment strategy of myocardial ischemic injury: 1.
It is necessary to further understand and reveal the mechanism and pathological changes of the myocardial ischemia microenvironment; 2.
Efficient drug therapy should Based on the design of a drug delivery system that is more sensitive to the ischemic microenvironment; 3.
It is necessary to develop a cascading ischemic microenvironment-responsive targeted therapy strategy; 4.
In order to achieve clinical translation, the biosafety and Compatibility should be the focus
.
This paper believes that the development of biomaterial delivery systems for myocardial ischemic injury is still in its initial stage.
Original link: https://onlinelibrary.